DIRS.INFO The most relevant business & tech news

☆ GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
▼ + stars: | 2024-01-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. GSK in November had forecast 2023 sales for the shot Arexvy between £900 million, or $1.1 billion, and £1 billion, or $1.26 billion, following its strong launch in the U.S. The company's RSV shot in part drove the higher forecast. The vaccine has about 70% market share for RSV, Walmsley added on Wednesday. Meanwhile, biotech company Moderna hopes to launch its own RSV vaccine this year.

Persons: Emma Walmsley, Walmsley, Arexvy, That's, Pfizer's, Albert Bourla, Bourla Organizations: GlaxoSmithKline, Stevenage, GSK, U.S, Pfizer, U.S . Food, Drug Administration, Moderna Locations: Britain, British, U.S, Canada, Japan

Uber shares rose 5% in extended trading on Friday after the ride-hailing company was added to the S&P 500 Index, replacing Sealed Air Corp. A company's stock price often rises on news that it's joining the S&P 500 because fund managers who track the benchmark, which gets updated each quarter, have to acquire the shares. Uber shares debuted on the New York Stock Exchange in 2019, but the company was burning cash as it had to pay drivers enough money to stay competitive in a low-margin business. Uber has a market cap of about $118 billion, while the median market cap of companies in the S&P 500 is just over $31 billion. WATCH: Uber into the S&P 500

Persons: Dara Khosrowshahi, it's, Nelson, Chai, Uber, Lloyd Walmsley, You've Organizations: Uber, Sealed Air Corp, Companies, New York Stock Exchange, UBS Locations: Davos, Switzerland

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ GSK lifts annual forecasts on strong launch of RSV vaccine
▼ + stars: | 2023-11-01 | by ( Eva Mathews | ) www.reuters.com time to read: +3 min

Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data. Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said. The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024. For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.

Persons: Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter Organizations: GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson Locations: London, United States, U.S, Europe, Japan, Delaware, Bengaluru

☆ How to play Alphabet's stock after its worst slide in more than a year, according to Wall Street
▼ + stars: | 2023-10-25 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Alphabet's latest quarterly results left some analysts questioning whether investors should be buying the dominant search engine right now, or opting instead for some of its tech peers. "If you own the stock, the bad news is probably out of the way," said Bernstein analyst Mark Shmulik. We take up our ad revenue estimates, pull cloud and margins down, and we end up right back where we started." Profit margins contracted and the company also said it expects capital spending to increase in the fourth quarter and in 2024. Alphabet sank 9.8% in midday trading Wednesday, on pace for its worst one-day decline since March 2020.

Persons: Bernstein, Mark Shmulik, Wells, Ken Gawrelski, Lloyd Walmsley, Gawrelski, Bank of America's Justin Post, James Lee, — CNBC's Michael Bloom Organizations: Google, Microsoft, UBS, Bank of America's

☆ Wall Street wants to know how Google's going to profit from AI
▼ + stars: | 2023-10-24 | by ( Jennifer Elias | ) www.cnbc.com time to read: +5 min

In the age of AI hype, few companies have used the word "AI" more than Google. Now, Wall Street wants know how it'll turn the hyped tech into dollars and cents. With SGE, Pichai said it'll be able to include "a wider range of sources on the results page, creating new opportunities for content to be discovered." Pichai added that with AI, he sees the opportunity to "evolve search and assistant for the next decade ahead." "It's probably the ultimate example of AI," Pichai said in response to Sheridan's question.

Persons: Bard, Lloyd Walmsley, Pichai, Brian Nowak, Morgan Stanley, Nowak, it'll, Philipp Schindler, we're, Schindler, UBS's Eric Sheridan, execs, Max, Google's, It's Organizations: Google, Deutsche Bank, YouTube, CNBC, Samsung, Toyota

☆ GSK raises $1.1 billion from Haleon stake sale
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsOct 6 (Reuters) - British drugmaker GSK (GSK.L) on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon (HLN.L), cutting its shareholding to 7.4% in the world's largest standalone consumer healthcare firm. The sale of 270 million shares at 328 pence apiece, represented a discount of about 2.5% to Haleon's last close of 336.25 pence on Thursday. Shares in Haleon were down 1.2% while GSK was marginally up 0.4% at 0800 GMT. Pfizer, which holds a 32% stake in Haleon, said in May it plans to cut its ownership in a "slow and methodical" manner within months. The British drugmaker and Pfizer have agreed to not sell any further Haleon shares for 60 days from the settlement of placing.

Persons: Dado Ruvic, Emma Walmsley, Prerna Bedi, Sonia Cheema, Elaine Hardcastle Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, London Stock Exchange, Pfizer, Thomson Locations: Haleon, British, Bengaluru

☆ What Instacart's IPO filing reveals for Uber and DoorDash investors
▼ + stars: | 2023-08-28 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Instacart's recent IPO filing delivered Wall Street some surprising insight into the grocery delivery business, and how competitors Uber and DoorDash 's could better harness advertising opportunities to unlock profit. Last week, the grocery delivery company brought an end to the tech IPO drought when it filed to go public on the Nasdaq Stock Market . And according to some Wall Street analysts, the filing revealed a better positioned company than expected, and one further along on the road to profitability than Uber and DoorDash at the time of their respective IPOs. Filings also revealed insight into customer behavior that both DoorDash and Uber can apply to their budding grocery segments. 'Cautious read-throughs' Despite widespread optimism about the long-term outlook for the grocery delivery business, the filing also revealed some near-term growth concerns for grocery delivery orders.

Persons: Uber, Bernstein, Nikhil Devnani, bode, Bernstein's Devnani, Lloyd Walmsley, Walmsley, — CNBC's Michael Bloom Organizations: Nasdaq, UBS, DASH

☆ Here's the trade on Amazon heading into earnings, according to analysts
▼ + stars: | 2023-08-03 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Wall Street analysts are bullish on Amazon heading into earnings. Here's how several analysts are trading Amazon ahead of its latest earnings report. Bank of America is also bullish, maintaining its buy rating and $154 price target into earnings, which suggests roughly 20% upside. "We continue to see an attractive set-up on the stock based on our Triple Trough Thesis (trough multiple, trough margin, and trough revenue growth). On Monday, the firm reiterated its buy rating and $145 price target, which suggests 13% upside from Wednesday's close.

Persons: StreetAccount, Morgan Stanley, Brian Nowak, Nowak, Lloyd Walmsley, Walmsley, Justin Post, Amazon's, Mark Mahaney's, Mahaney, — CNBC's Michael Bloom Organizations: Amazon Web Services, UBS, Bank of America, AWS, Triple, Citi Locations: 1Q23

☆ Google, Microsoft, and Meta can't stop talking about A.I. — here's why Apple rarely mentions it
▼ + stars: | 2023-07-28 | by ( Kif Leswing | ) www.cnbc.com time to read: +6 min

Stefani Reynolds | AFP | Getty ImagesMicrosoft, Google and Meta are rallying everyone around AI, even though the future is murkyGoogle launched Bard AI, it's own chatbot to rival Microsoft and OpenAI's ChatGPT. Google, for example, has announced its plans to revamp its search engine using an AI model called Search Generative Experience. Google and Pichai say that the company's text-generating AI models will make its search engine better and could even answer questions that normal Google search can't. Zuckerberg was effusive about AI technology and its applications in virtual reality, ad targeting and recommending content from accounts users don't follow. UBS analyst Lloyd Walmsley wrote this week that generative AI was still an "overhang" over Google.

Persons: Tim Cook, Narendra Modi, Stefani Reynolds, ChatGPT, Jonathan Raa, OpenAI's, Amy Hood, we'll, Nadella, Pichai, it's, Zuckerberg, Meta, Bing, Gartner, Mark Murphy, Laura Martin, Lloyd Walmsley, monetization, Walmsley, Scott Olson Organizations: India's, White, AFP, Getty, Microsoft, Google, Nurphoto, Meta, Apple, Big Tech, Nvidia, Venture, JPMorgan, UBS Locations: Washington ,, iPhones, Brussels, Belgium, Chicago

☆ Wall Street analysts become even more bullish on Meta after its latest earnings report
▼ + stars: | 2023-07-27 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

Meta has had a breakout year in 2023 — and Wall Street analysts think the stock has even further room to grow after company's latest quarterly report. The new target price implies more than 25% upside from Wednesday's close. Bank of America analyst Justin Post also increased his price target on Meta shares to $375 from $350. META YTD mountain Meta shares in 2023 Meanwhile, UBS hiked its price target to $400 from $335, implying 34% further upside. He reiterated his overweight rating while lifting his price target to $425 from $300, one of the highest on the Street.

Persons: Meta, Morgan Stanley, Brian Novak, Novak, Justin Post, Goldman Sachs, Eric Sheridan, Sheridan, Wells, Ken Gawrelski, Gawrelski, Stephen Ju, Ju, UBS's Lloyd Walmsley, Walmsley, Doug Anmuth, — CNBC's Michael Bloom Organizations: Wall Street, Meta, Bank of America, Citi, Reality Labs, UBS, Credit Suisse Locations: opex

GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.

Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru

☆ GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
▼ + stars: | 2023-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its blockbuster shingles shot. Last month, GSK's RSV shot became the first to win approval in the U.S. and European Union for the treatment of adults 60 and above. The company has not provided estimates for how much revenue the RSV shot will rake in this year following its launch. GSK's vaccine against shingles, a viral infection that causes a painful rash, is the company's top-selling drug. Investors are hoping that Shingrix and GSK's RSV shot will help offset patent expirations for some of the company's blockbuster HIV drugs in a few years.

Persons: Emma Walmsley, Walmsley Organizations: GSK, Union, U.S, European Union, Investors Locations: London, U.S, Japan, Canada

☆ UBS downgrades Google-parent Alphabet, cites stiffer competition and generative A.I. headwinds
▼ + stars: | 2023-06-26 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

The bank downgraded the tech giant to neutral from buy, albeit with a higher $132 per share price target compared to the previous $123 forecast. UBS' new price target implies roughly 8% upside for Alphabet stock compared to its $122.34 close on Friday. GOOGL YTD mountain Alphabet stock has added nearly 40% from January. UBS analyst Lloyd Walmsley noted he finds difficulty forecasting more upside for Alphabet, noting revenue headwinds remain in the near-term from new search competition. Walmsley highlighted three risks stemming from generative AI over the medium-term: stiffer competition, pressure to margins and hiccups in monetizing the technology.

Persons: Lloyd Walmsley, Walmsley, GOOG, — CNBC's Michael Bloom Organizations: UBS, Google

☆ UBS' Lloyd Walmsley says, there are more clean plays on generative A.I. than in Alphabet
▼ + stars: | 2023-06-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUBS' Lloyd Walmsley says, there are more clean plays on generative A.I. than in AlphabetLloyd Walmsley, UBS internet analyst, joins 'Power Lunch' to discuss UBS' downgrade of Alphabet to neutral.

Persons: Lloyd Walmsley Organizations: UBS

☆ Cramer's Lightning Round: I am not a believer in Coinbase
▼ + stars: | 2023-05-15 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Chewy's year-to-date stock performance. Stock Chart Icon Stock chart icon Enterprise Products Partners year-to-date stock performance. Stock Chart Icon Stock chart icon Coinbase Global's year-to-date stock performance. Stock Chart Icon Stock chart icon Amgen's year-to-date stock performance. Stock Chart Icon Stock chart icon Snowflake's year-to-date stock performance.

Companies GSK plc FollowLONDON, April 26 (Reuters) - British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU's pharmaceuticals industry risks forcing companies to invest and innovate elsewhere, which would hurt EU efforts to improve access to medicines. The European Commission will publish its long-awaited draft on Wednesday, detailing the biggest overhaul of medical laws in 20 years. The Commission has said the reforms aim to tackle unequal access to medicines across Europe while retaining the region's competitiveness for pharma companies developing and bringing new treatments to market. However, pressure to weaken market exclusivity protections could discourage companies from researching and launching treatments in Europe, she added. Reporting by Maggie Fick and Natalie Grover Editing by David GoodmanOur Standards: The Thomson Reuters Trust Principles.

☆ What the loss of Samsung search engine business could mean for Alphabet's stock
▼ + stars: | 2023-04-18 | by ( Brian Evans | ) www.cnbc.com time to read: +4 min

A weekend report from The New York Times said Samsung is thinking of switching its default search engine to Microsoft's Bing. Samsung represents roughly 27% of the smartphone market and has a 60% share of Android phones, according to Barclays. Barclays estimates that Samsung represents about $20 billion of Google's gross revenue and $7.3 billion of operating income. If the cellphone maker were to move away from the search engine, Google may have to recapture 70% of lost queries organically to recoup the lost operating income, the firm found. He thinks Google will remain the search engine heavyweight and successfully integrate Bard to rival Bing's use of ChatGPT.

☆ Cramer's getting the State of Health Care with the CEO of GSK
▼ + stars: | 2023-03-29 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer's getting the State of Health Care with the CEO of GSKMad Money host Jim Cramer talks to GSK CEO Emma Walmsley about the state of the healthcare sector.

☆ UBS says this social media stock can rally more than 25% on plans to improve advertising
▼ + stars: | 2023-03-27 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Pinterest could see big gains ahead as new leadership pushes the e-commerce platform to unlock untapped advertising opportunities, according to UBS. Analyst Lloyd Walmsley upgraded the stock to buy from neutral. Walmsley said Pinterest's partner monetization strategy began showing "rapid improvement" in the international space. The company has also seen an increase in ad loads stemming from improved ad density and relevance. Still, he said the company could benefit from a large global partner to help, while smaller local partners can provide additional support.

☆ Meta can't make any big acquisitions right now, as its $40 billion war chest starts going towards appeasing Wall Street investors
▼ + stars: | 2023-03-17 | by ( Asia Martin | ) www.businessinsider.com time to read: +5 min

Meta is repurchasing $40 billion worth of stock from investors, even as it cuts jobs. But as Meta's "year of efficiency" continues, Mark Zuckerberg needs to put its $40.74 billion cash pile to a more boring — but perhaps more practical — use: making shareholders happy. Since 2012, Meta Platforms, formerly called Facebook, has acquired over 100 companies, including big names like WhatsApp, Instagram, and Oculus. The social networking giant's revenue has ballooned over the years from $5 billion in 2012 to $116 billion last year. Meta can't do big acquisitions, and it needs to win over Wall StreetAntitrust scrutiny continues to be a thorn in its side when it comes to acquisitions.

☆ How GSK plans to replenish its depleted medicine cabinet
▼ + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.

☆ UBS says these stocks posted high-quality earnings this season
▼ + stars: | 2023-02-22 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Now that Wall Street is about to close the books on yet another earnings season, it's time to see which names posted higher-quality earnings than others, according to UBS. In the S & P 500, about 86% of companies reported quarterly earnings thus far, according to FactSet data. However, UBS' strategist Keith Parker worries that earnings quality is an "overhang," saying the divide between earnings and operating cash flow for companies points to roughly 15% earnings-per-share downside for at-risk stocks. These stocks are in the S & P 1500, have a market cap greater than $3 billion, excluding stocks in financial, real estate and utilities. Meanwhile, Humana demonstrated strong earnings quality because of its leading position in the Medicare Advantage market, according to UBS analyst Kevin Caliendo.

☆ Heavyweight tech battle: How Microsoft and Alphabet stack up against each other in the A.I. war
▼ + stars: | 2023-02-10 | by ( Samantha Subin | ) www.cnbc.com time to read: +9 min

"It's a new day in search," Microsoft CEO Satya Nadella said Tuesday during an AI event held at the company's headquarters, saying that the "race starts today." So far, Microsoft is making significant headway within AI and rising in popularity in the tech world. Alphabet, he added, "got beaten to market by Microsoft" despite its investments in the space. Alphabet Microsoft may be taking the lead on AI in the near term, but investors shouldn't sleep on Alphabet just yet. "We believe GOOGL has the AI tech and scale to maintain/grow its leading user base," said Morgan Stanley's Brian Nowak in a Thursday note.

☆ Microsoft may have won the A.I. battle, but Alphabet could win the war, analysts say
▼ + stars: | 2023-02-09 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Microsoft won the first round in the battle to become the next big artificial intelligence leader, but analysts think Alphabet 's ability to overtake its competition in the long-run shouldn't be underestimated. "We think Google's big reveal is still to come, which we would expect in weeks and not months." On the heels of its multibillion dollar investment in ChatGPT-creator OpenAI, Microsoft on Tuesday announced new AI versions of its Bing search engine and Edge browser. "We believe GOOGL has the AI tech and scale to maintain/grow its leading user base," wrote Morgan Stanley's Brian Nowak. He also expects Google's AI product visibility to improve over the next few months — and easily offset some higher AI search costs.

Search resuls for: "Walmsley"

25 mentions found